Genmab A/S (NASDAQ:GMAB) Shares Gap Down to $29.43

Genmab A/S (NASDAQ:GMAB) shares gapped down prior to trading on Wednesday . The stock had previously closed at $29.43, but opened at $28.78. Genmab A/S shares last traded at $28.83, with a volume of 30,523 shares trading hands.

Analysts Set New Price Targets

A number of research firms recently commented on GMAB. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a research note on Thursday, April 4th. Truist Financial reissued a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a research note on Tuesday, March 26th. Morgan Stanley reissued an “underweight” rating on shares of Genmab A/S in a research note on Tuesday, March 26th. BMO Capital Markets raised Genmab A/S from a “market perform” rating to an “outperform” rating and increased their target price for the company from $46.00 to $48.00 in a research note on Friday, February 23rd. Finally, Citigroup cut Genmab A/S from a “neutral” rating to a “sell” rating in a research note on Monday, January 22nd. Three research analysts have rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, Genmab A/S presently has an average rating of “Hold” and a consensus target price of $48.50.

Genmab A/S Stock Down 0.7 %

The firm’s 50-day simple moving average is $29.36 and its 200-day simple moving average is $30.34. The firm has a market capitalization of $18.73 billion, a PE ratio of 29.51, a price-to-earnings-growth ratio of 2.05 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Wednesday, February 14th. The company reported $0.36 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.02. The company had revenue of $675.29 million during the quarter, compared to analyst estimates of $678.14 million. Genmab A/S had a net margin of 26.50% and a return on equity of 18.06%. On average, equities research analysts forecast that Genmab A/S will post 1.06 earnings per share for the current year.

Institutional Trading of Genmab A/S

Institutional investors have recently modified their holdings of the company. First Manhattan Co. purchased a new stake in shares of Genmab A/S during the fourth quarter worth about $26,000. Headlands Technologies LLC purchased a new stake in shares of Genmab A/S during the third quarter worth about $27,000. Pinnacle Bancorp Inc. boosted its holdings in shares of Genmab A/S by 315.8% during the fourth quarter. Pinnacle Bancorp Inc. now owns 840 shares of the company’s stock worth $27,000 after purchasing an additional 638 shares during the period. GAMMA Investing LLC lifted its holdings in Genmab A/S by 194.0% in the first quarter. GAMMA Investing LLC now owns 1,135 shares of the company’s stock worth $34,000 after buying an additional 749 shares during the period. Finally, NBC Securities Inc. purchased a new stake in Genmab A/S in the third quarter worth about $37,000. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.